While immunotherapy monotherapy demonstrates substantial efficacy in NSCLC patients with high PD-L1 expression (tumor proportion score ≥ 50%), its benefits in PD-L1-low populations mirror those of conventional chemotherapy (26–29). This evidence concerns the gene CD274 and neoplasm.